DK1309315T3 - Hurtigt disintegrerende oral valdecoxib-formulering - Google Patents

Hurtigt disintegrerende oral valdecoxib-formulering

Info

Publication number
DK1309315T3
DK1309315T3 DK01964122T DK01964122T DK1309315T3 DK 1309315 T3 DK1309315 T3 DK 1309315T3 DK 01964122 T DK01964122 T DK 01964122T DK 01964122 T DK01964122 T DK 01964122T DK 1309315 T3 DK1309315 T3 DK 1309315T3
Authority
DK
Denmark
Prior art keywords
molded article
rapidly disintegrating
oral cavity
disintegrating oral
cyclooxygenase
Prior art date
Application number
DK01964122T
Other languages
English (en)
Inventor
Tugrul T Kararli
Trang T Le
Mark J Kontny
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of DK1309315T3 publication Critical patent/DK1309315T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
DK01964122T 2000-08-18 2001-08-17 Hurtigt disintegrerende oral valdecoxib-formulering DK1309315T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22648700P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
DK1309315T3 true DK1309315T3 (da) 2006-10-09

Family

ID=22849097

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01964122T DK1309315T3 (da) 2000-08-18 2001-08-17 Hurtigt disintegrerende oral valdecoxib-formulering

Country Status (14)

Country Link
US (1) US20020071857A1 (da)
EP (1) EP1309315B1 (da)
JP (1) JP2004506680A (da)
AT (1) ATE329583T1 (da)
AU (1) AU2001285011A1 (da)
CA (1) CA2419592A1 (da)
CY (1) CY1105319T1 (da)
DE (1) DE60120710T2 (da)
DK (1) DK1309315T3 (da)
ES (1) ES2265439T3 (da)
MX (1) MXPA03001407A (da)
NZ (1) NZ524124A (da)
PT (1) PT1309315E (da)
WO (1) WO2002015884A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429736A2 (en) * 2001-09-26 2004-06-23 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
HUP0401776A2 (hu) * 2001-10-10 2004-12-28 Pharmacia Corporation Intraorálisan széteső valdekoxib készítmények porlasztásos szárítási eljárással előállítva
WO2003049720A1 (en) * 2001-12-07 2003-06-19 Merck & Co., Inc. Combination therapy comprising a cyclooygenase-2 inhibitor
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP4739217B2 (ja) * 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
BRPI0302736B8 (pt) * 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
GB2423710A (en) * 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
ATE482693T1 (de) * 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
JP2008540644A (ja) * 2005-07-15 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド 新規粒質化方法及びそれから生成される粒質物
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
EP2604257B1 (en) * 2007-08-07 2017-06-28 Acelrx Pharmaceuticals, Inc. Oral transmucosal dosage forms comprising sufentanil and triazolam
EP2222282A1 (en) * 2007-11-15 2010-09-01 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
BRPI0822655A2 (pt) 2008-06-04 2015-06-30 Colgate Palmolive Co Implemento e sistema para cuidado oral
US20100075930A1 (en) * 2008-09-03 2010-03-25 Yoel Ovil Salicylic salt compositions and related method of treatment of cardiac conditions
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2895168A4 (en) * 2012-09-13 2016-08-31 Cba Pharma Inc TETRANDRINE MEDICINAL FORMULATIONS AND METHOD
NZ732808A (en) 2014-12-23 2021-12-24 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3740284A4 (en) * 2018-01-21 2021-10-13 Kastner, Bernie D. PREPARATION AND METHOD FOR TREATMENT OF MIGRAINE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
JP2807346B2 (ja) * 1991-12-24 1998-10-08 山之内製薬株式会社 口腔内崩壊製剤及びその製造法
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
CA2178686A1 (en) * 1995-06-13 1996-12-14 Leslie G. Humber Oral formulations of s(+)-etodolac
BR9709097A (pt) * 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
IT1298732B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
AU764875B2 (en) * 1998-11-12 2003-09-04 Merck & Co., Inc. Combination of a GABA-A alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
RU2216319C1 (ru) * 1999-11-30 2003-11-20 Панацея Биотек Лимитед Быстрорастворимая фармацевтическая композиция в виде твердой лекарственной формы с пролонгированным сладким вкусом и способ ее получения

Also Published As

Publication number Publication date
DE60120710D1 (de) 2006-07-27
ATE329583T1 (de) 2006-07-15
CA2419592A1 (en) 2002-02-28
AU2001285011A1 (en) 2002-03-04
US20020071857A1 (en) 2002-06-13
PT1309315E (pt) 2006-09-29
CY1105319T1 (el) 2010-03-03
DE60120710T2 (de) 2007-06-14
EP1309315B1 (en) 2006-06-14
WO2002015884A3 (en) 2002-07-25
EP1309315A2 (en) 2003-05-14
ES2265439T3 (es) 2007-02-16
WO2002015884A2 (en) 2002-02-28
JP2004506680A (ja) 2004-03-04
MXPA03001407A (es) 2003-06-06
NZ524124A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
DK1309315T3 (da) Hurtigt disintegrerende oral valdecoxib-formulering
EP1120109A3 (en) Rapidly disintegrating and fast dissolving solid dosage form
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
MX9308188A (es) Glucomanano de konjac facilmente disponible, como un excipiente de liberacion sostenida.
NZ734446A (en) Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor
MY128368A (en) Method for producing quickly decomposable solid pharmaceutical preparations
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
CA2990445A1 (en) Thermo-kinetic mixing for pharmaceutical applications
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
NO20034417L (no) Engangs vaginalkanyle for samtidig administrasjon av medikamenter i ulike former
DE60103276D1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
WO2010019279A8 (en) Pharmaceutical compositions configured to deter dosage form splitting
DE60123447D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe
DE69830176D1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
CO5160319A1 (es) Formulaciones de liberacion controlada de metamizol
Pandey et al. Orodispersible tablets-a review
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
CN105581991A (zh) 一种酒石酸唑吡坦舌下片及其制备方法
ECSP993186A (es) Formulaciones de liberacion controlada de metamizol
EP4008314A3 (en) Thermo-kinetic mixing for pharmaceutical applications
CY1118235T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ii
Nicholson Ask the doctor. In your article on Alzheimer's disease (March, 1999), you mention" high doses of vitamin E" as helpful in slowing the progression of the condition. Specifically, what dose is recommended?